Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital of Cologne
With
Bencard Allergie GmbH
This prospective open multi-centre non-interventional study was initiated to document the tolerability and the safety profile of the subcutaneous allergen-specific immunotherapy with Acarovac® in house dust mite allergic patients in routine medical care.
During the up-dosing phase with Acarovac®, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
Data on tolerability are documented by the physicians.
Age
5–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients of the age of 5 years and older suffering from a house dust mite induced allergic rhinitis
You may not be if
Patients suffering from acute or chronic infections or inflammations
Patients suffering from secondary modifications of the target organ with function impairment (emphysema, bronchiectasis)
Patients suffering from severe and uncontrolled asthma
Patients with a known severe autoimmune disease
Patients with active malignant disease
Patients requiring beta-blockers
Patients having any contraindication for the use of adrenaline
Patients with a hypersensitivity to the excipients of the drug
Clareo Health | Non-interventional Study to Assess the Tolerability and the Safety Profile of SCIT Therapy With Acarovac® Hausstaubmilbe
